Skip to content

Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism

Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03583684
Acronym
PRT-I
Enrollment
36
Registered
2018-07-11
Start date
2018-12-07
Completion date
2026-11-30
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism, Autism Spectrum Disorder

Keywords

Pivotal Response Treatment, Imaging

Brief summary

Autism spectrum disorder (ASD) is a very heterogeneous disorder with limited empirically validated behavioral and biological interventions. The goal of this pilot investigation is to apply a biologically-based approach to identify predictors of treatment response in children with ASD who are receiving Pivotal Response Treatment (PRT), an evidence-based behavioral intervention. Specifically, the investigators propose to identify neuroimaging biomarkers of treatment response to a PRT program (PRT-P) targeting language deficits in young children with ASD who will be randomized to either PRT-P or to a delayed treatment group (DTG).

Interventions

BEHAVIORALPivotal Response Treatment Program (PRT-P)

The Pivotal Response Treatment Program (PRT-P) will consist of 3 parent-only sessions (60-90 min) and 13 family sessions with the parent and child (60-90 min). These 16 sessions are once per week over a 16 week period.

Sponsors

National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH
Stanford University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
2 Years to 4 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of Autism Spectrum Spectrum Disorder (ASD) based on clinical interview and Diagnostic and Statistical Manual, 5th edition (DSM-5) and confirmed using the Autism Diagnostic Interview Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) and/or Brief Observation of Symptoms of Autism (BOSA) and/or Childhood Autism Rating Scale- Second Edition (CARS-2). * Outpatients between 2.0 and 4.11 years of age of either gender, * Children of all cognitive levels will be included as long as they are able to participate in the testing procedures to the extent that valid standard scores can be obtained * Language delay as measured by the Preschool Language Scale, 5th Edition (PLS-5) \[at least 1 standard deviation behind for children age 2 and 3 years; and 2 standard deviations behind for children age 4\], * Stable psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation, * Stable treatment \[Applied Behavior Analysis (ABA), Floortime, or other interventions\], speech therapy, and school placement for at least 1 month prior to baseline measurements with no expected changes during study participation, * No more than 60 minutes of 1:1 speech therapy per week, * The child's exposure to the English language must be sufficient that administration of standardized tests in English is appropriate for measuring progress, * The availability of at least one parent who can consistently participate in the training sessions and related activities, and * Successful completion of baseline brain scan.

Exclusion criteria

* Current or life-time diagnosis of severe psychiatric disorder (e.g., bipolar disorder), * Genetic abnormality (e.g., Fragile X) * Presence of active medical problem (e.g., unstable seizure disorder), * Receiving more than 15 hours of in home 1:1 Applied Behavior Analysis (ABA) per week * Magnetic Resonance (MR) contraindication (e.g., the presence of ferrous metal), or * Previous adequate Pivotal Response Treatment (PRT) trial.

Design outcomes

Primary

MeasureTime frame
Change in Number of Child Utterances During a Structured Lab Observation (SLO)Baseline, 16 Weeks

Secondary

MeasureTime frame
Change on MacArthur-Bates Communication Development Inventory (CDI)Baseline, 16 Weeks

Other

MeasureTime frame
Change on Vineland Adaptive Behaviors Scales, 3rd EditionBaseline, 16 Weeks
Change on Clinical Global Impressions Scale (CGI)Baseline, 16 Weeks
Change on the Brief Observation of Social Communication Change (BOSCC) direct child observation assessmentBaseline, 16 Weeks
Change on Preschool Language Scale, 5th Edition (PLS-5)Baseline, 16 Weeks
Change on Family Empowerment Scale (FES)Baseline, 16 Weeks
Change on General Self Efficacy Scale (GSES)Baseline, 16 Weeks
Change on Parent Stress Index (PSI)Baseline, 16 Weeks
Change on Mullen Scales of Early LearningBaseline, 16 Weeks

Countries

United States

Contacts

Primary ContactEstefania Millan, MA
mmillan2@stanford.edu(650) 736-1235
Backup ContactJohn Hegarty, PhD
hegartyj@stanford.edu(650) 736-1235

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026